ANTIBODYSHOP®

PRODUCT SPECIFICATION
05/05/2008

Anti-uPA (human, urokinase plasminogen activator)
Mouse monoclonal antibody

Subclass: IgG1

PRODUCT NO. **MON U-12**

PRESENTATION

Preparation:	Protein-A purified
Content:	Available in 200 µL and 1 mL volumes, 1 mg/mL
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	In the dark at 4-8ºC

ANTIGEN

Urokinase plasminogen activator (uPA) is a serine protease. It converts the abundant proenzyme plasminogen to active plasmin and plays a key role in cancer invasion and a variety of tissue remodelling processes such as wound healing, mammary gland involution and placental development (1-3). Elevated levels of uPA are associated with poor prognosis in many types of cancer (2-5).

IMMUNOGEN

Native human uPA

SPECIFICITY

MON U-12 is specific for human uPA. No reaction with human tissue plasminogen activator (tPA) is seen when tested by ELISA, immunoblotting and enzyme inhibition. No reaction with any other human plasma proteins is seen when tested by immunoblotting.

EPITOPE SPECIFICITY

MON U-12 binds to the A-chain of uPA (6)

REACTIVITY

MON U-12 binds single and two-chain uPA and uPA/uPAR complex. A reaction is seen with amino terminal fragment (ATF) but not with LMW uPA. MON U-12 reacts with non-reduced uPA but not with reduced uPA in Western blotting. MON U-12 inhibits the enzymatic activity of uPA and does not block the binding of uPA to uPAR. MON U-12 can be used on frozen sections in immunohistochemistry applications (7,8).

CULTURE MEDIUM

RPMI 1640 with 10% fetal calf serum

FUSION PARTNER

NSI-Ag 4/1

IMMUNIZATION

Female BALB/c mice immunized by intradermal injection

APPLICATION

Method	Usability	Dilution guideline	References
ELISA	Yes		5
Immunoblotting	Yes		
Immunohistochemistry	Yes		7,8

REFERENCES

1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266.
2. Andreasen PA, Kjøller L, Christensen L, Duffey MJ (1997) The urokinase plasminogen activator system in cancer metastasis. Int J Cancer 2:1-22.
3. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J (2005) Plasminogen activation and cancer. Thromb Haem 93:676-681.
4. Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk acording to urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). Cancae Res 62:4617-22.
5. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner, N., Mouridsen, H.T., Danø. K. & Blichert-Toft, M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521.
6. Kaltoft K, Nielsen LS, Zeuthen J, Danø K (1982) Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci USA 79:3720-3723.
7. Grøndahl-Hansen J, Ralfkiær E, Nielsen LS, Kristensen P, Frentz G, Danø K (1987) Immunohistochemical localization of urokinase and tissue type plasminogen activators in psoriatic skin. J Invest Dermatol 88:28-32.
8. Grøndahl-Hansen J, Ralfkiær E, Kirkeby LT, Kristensen P, Lund LR, Danø K (1991) Localization of urokinase type

BioPorto Diagnostics A/S • Grusbakken 8 • DK-2820 Gentofte • Denmark • info@bioporto.com • www.bioporto.com
Phone: +45 4529 0000 • Fax: +45 4529 0001 • CVR / Vat: DK-1864 5882